AVTX vs. AQST, IMMP, YMAB, OLMA, NGNE, RZLT, ATYR, CMPX, AVIR, and ACIU
Should you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Aquestive Therapeutics (AQST), Immutep (IMMP), Y-mAbs Therapeutics (YMAB), Olema Pharmaceuticals (OLMA), Neurogene (NGNE), Rezolute (RZLT), Atyr PHARMA (ATYR), Compass Therapeutics (CMPX), Atea Pharmaceuticals (AVIR), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry.
Avalo Therapeutics vs.
Aquestive Therapeutics (NASDAQ:AQST) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation.
Avalo Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -59.75%. Aquestive Therapeutics' return on equity of 0.00% beat Avalo Therapeutics' return on equity.
Aquestive Therapeutics received 206 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 68.17% of users gave Aquestive Therapeutics an outperform vote while only 33.33% of users gave Avalo Therapeutics an outperform vote.
In the previous week, Aquestive Therapeutics had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 5 mentions for Aquestive Therapeutics and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.88 beat Aquestive Therapeutics' score of 0.78 indicating that Avalo Therapeutics is being referred to more favorably in the news media.
32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 7.9% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 0.3% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Aquestive Therapeutics has higher revenue and earnings than Avalo Therapeutics.
Aquestive Therapeutics has a beta of 2.71, meaning that its share price is 171% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
Aquestive Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 254.84%. Avalo Therapeutics has a consensus target price of $40.00, suggesting a potential upside of 492.59%. Given Avalo Therapeutics' higher probable upside, analysts plainly believe Avalo Therapeutics is more favorable than Aquestive Therapeutics.
Summary
Aquestive Therapeutics beats Avalo Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Avalo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avalo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AVTX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free AVTX Stock Alerts